THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

SEC probes Biogen options trades

Spike in activity took place 19 days before Tysabri halt

By Jeffrey Krasner
Globe Staff / March 12, 2005

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

The Securities and Exchange Commission is investigating a tremendous surge in options trading in shares of Biogen Idec that occurred nearly three weeks before the company temporarily suspended sales of its multiple sclerosis drug Tysabri, according to a lawyer who has been briefed on the matter. (Full article: 891 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass